Remepy raises $36 million Series A as it prepares AI-driven Parkinson’s treatment for Phase III
The Israeli company’s Hybridopa program has shown improvements in motor and non-motor symptoms in Phase IIa trials, while a new partnership with Merck is expanding its approach into rare tumors.
Remepy, a developer of hybrid drugs that combine prescription medicines with personalized, AI-driven therapeutic applications, has raised $36 million in a Series A round led by O.G. Venture Partners and M Ventures, the strategic investment arm of Merck KGaA, Darmstadt, Germany.
The round included participation from existing and new investors, including NFX, Vine Ventures, TechAviv, 97212 Ventures, Qumra Capital, Fresh Fund, PsyMed Ventures, Tadmor Group and IT-Farm Corp. The latest financing brings the company's total capital raised to $62 million.
The proceeds will be used to advance Remepy's pharmaceutical co-development partnerships, expand its Hybrid Drug pipeline and platform, and fund global Phase III clinical development of Hybridopa, the company's lead program for Parkinson's disease. The Phase III program is expected to begin in the fourth quarter of 2026.
Remepy was founded in 2022 by serial entrepreneur Dr. Michal Tsur, who was previously among the founders of Cayota and Kaltura, alongside Or Shoval, Eran Etam and Prof. Amir Amedi, director of the Brain and Imaging Institute at Reichman University. Tsur and Shoval currently serve as the company's co-CEOs. Remepy has approximately 60 employees and is based in Ramat Gan.
Remepy is developing what it describes as a new class of medicines that combines prescription drugs with personalized, AI-driven therapeutic apps. The company's Hybrid Drugs integrate pharmacological treatment with adaptive physical, cognitive and behavioral interventions into a single treatment.
The model is intended to allow multidisciplinary care to be delivered to larger numbers of patients through the standard prescription model, rather than requiring separate treatment programs for different aspects of a patient's condition.
The company has also positioned the approach as a way for pharmaceutical companies to extend existing drugs and develop new intellectual property around them. Its platform is designed to combine the pharmaceutical component with software that can adapt therapeutic interventions to individual patients.
Remepy recently announced a strategic collaboration with Merck KGaA to develop Hybrid Drugs across multiple indications, beginning with rare tumors.
The company's lead program, Hybridopa, is being developed for Parkinson's disease. The treatment has generated encouraging Phase IIa clinical results showing improvements in both motor and non-motor symptoms. The company said the results are also supported by peer-reviewed publications examining the biological mechanisms underlying the treatment's effects.
Remepy is now preparing Hybridopa for global Phase III development, which is expected to begin in the fourth quarter of 2026. Hybridopa remains an investigational product and has not been approved by the FDA.
The company said the Hybrid Drug model is also gaining momentum from emerging FDA frameworks for drug-software combination products and greater regulatory alignment around such treatments.
“Through a combination of biotechnology, artificial intelligence and digital health, Remepy is redefining how medicines are developed and delivered,” said Ziv Kop, managing partner at O.G. Venture Partners Israel.
